An experimental cell therapy developed at the University of Wisconsin Health in Madison has received the FDA’s fast-track designation.
The treatment, developed through a partnership between UW Health and the UW School of Medicine and Public Health, is designed to treat xerostomia, according to a May 7 news release.
Xerostomia, or dry mouth, is a common side effect of radiation for head and neck cancer. The cell therapy is currently in a phase 1 trial at the health system’s Carbone Clinical Center in Madison.
A UW Health spokesperson told Becker’s this is the first FDA fast-track designation since 2012 given to an organization that is not a private commercial drug developer.
The fast-track designation expedites the agency’s review of a drug candidate that treats a serious condition and meets an unmet clinical need.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
